Diagnostic efficacy of fecal calprotectin combined with a high-sensitivity quantitative fecal immunochemical test for colorectal tumors

Figure 1 The distribution of fecal calprotectin and high-sensitivity quantitative fecal immunochemical test in the control, adenoma, and colorectal cancer groups. A: The difference in fecal calprotectin (FC) between the control group and the adenoma group was not significant (adjusted P = 0.547 > 0.05 after Bonferroni correction). Significant differences in FC were found between the control group and the colorectal cancer (CRC) group, as well as between the adenoma group and the CRC group (P < 0.001), with FC levels in the CRC group being significantly higher than those in the control group and the adenoma group; B: Significant differences were observed between the control group and the adenoma group (adjusted P = 0.039 < 0.05 after Bonferroni correction), as well as between the control group and the CRC group, and between the adenoma group and the CRC group (P < 0.001). High-sensitivity quantitative fecal immunochemical test levels in the CRC group were significantly higher than those in the control group and the adenoma group. FC: Fecal calprotectin; CRC: Colorectal cancer; hs-qFIT: High-sensitivity quantitative fecal immunochemical test.